Page 26 - ARNM-2-4

Advances in Radiotherapy
& Nuclear Medicine 68 Ga-PSMA PET CT/MRI in prostate cancer

Availability of data positron emission tomography-targeted biopsy for detection
of clinically significant prostate cancer: A systematic review
Not applicable. and meta-analysis. Eur Urol Oncol. 2022;5(4):390-400.
References doi: 10.1016/j.euo.2022.04.006

1. Wang L, Lu B, He M, et al. Prostate cancer incidence and 11. Evangelista L, Zattoni F, Cassarino G, et al. PET/MRI in
mortality: Global status and temporal trends in 89 countries prostate cancer: A systematic review and meta-analysis. Eur
from 2000 to 2019. Front Public Health. 2022;10:811044. J Nucl Med Mol Imaging. 2021;48(3):859-873.
doi: 10.3389/fpubh.2022.811044 doi: 10.1007/s00259-020-05025-0
2. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate 12. Satapathy S, Singh H, Kumar R, et al. Diagnostic accuracy
cancer, version 2.2019, NCCN clinical practice guidelines in of 68Ga-PSMA PET/CT for initial detection in patients with
oncology. J Natl Compr Canc Netw. 2019;17(5):479-505. suspected prostate cancer: A systematic review and meta-
analysis. AJR Am J Roentgenol. 2021;216(3):599-607.
doi: 10.6004/jnccn.2019.0023
doi: 10.2214/AJR.20.23912
3. Ghai S, Haider MA. Multiparametric-MRI in the diagnosis
of prostate cancer. Indian J Urol. 2015;31(3):194-201. 13. Ptasznik G, Moon D, Buteau J, et al. A systematic review of
the variability in performing and reporting intraprostatic
doi: 10.4103/0970-1591.159606 prostate-specific membrane antigen positron emission
4. Bouchelouche K, Choyke PL. Advances in prostate-specific tomography in primary staging studies. Eur Urol Open Sci.
membrane antigen PET of prostate cancer. Curr Opin Oncol. 2023;50:91-105.
2018;30(3):189-196. doi: 10.1016/j.euros.2023.01.010
doi: 10.1097/CCO.0000000000000439 14. Caracciolo M, Castello A, Urso L, et al. The role of [68Ga]
5. Zhen L, Liu X, Yegang C, et al. Accuracy of multiparametric PSMA PET/CT for clinical suspicion of prostate cancer
magnetic resonance imaging for diagnosing prostate cancer: in patients with or without previous negative biopsy:
A systematic review and meta-analysis. BMC Cancer. A systematic review. Cancers (Basel). 2022;14(20):5036.
2019;19(1):1244. doi: 10.3390/cancers14205036
doi: 10.1186/s12885-019-6434-2 15. Sood A, Kishan AU, Evans CP, et al. The impact of positron
6. Rosenkrantz AB, Ginocchio LA, Cornfeld D, et al. emission tomography imaging and tumor molecular
Interobserver reproducibility of the PI-RADS version 2 profiling on risk stratification, treatment choice, and
lexicon: A multicenter study of six experienced prostate oncological outcomes of patients with primary or relapsed
radiologists. Radiology. 2016;280(3):793-804. prostate cancer: An international collaborative review of the
existing literature. Eur Urol Oncol. 2024;7(1):27-43.
doi: 10.1148/radiol.2016152542
doi: 10.1016/j.euo.2023.06.002
7. Richenberg J, Løgager V, Panebianco V, et al. The primacy
of multiparametric MRI in men with suspected prostate 16. Yadav D, Hwang H, Qiao W, et al. 18F-fluciclovine versus
cancer. Eur Radiol. 2019;29(12):6940-6952. PSMA PET imaging in primary tumor detection during
initial staging of high-risk prostate cancer: A systematic
doi: 10.1007/s00330-019-06166-z
review and meta-analysis. Radiol Imaging Cancer.
8. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate- 2022;4(2):e210091.
specific membrane antigen PET-CT in patients with doi: 10.1148/rycan.210091
high-risk prostate cancer before curative-intent surgery
or radiotherapy (proPSMA): A prospective, randomised, 17. Zhao Y, Simpson BS, Morka N, et al. Comparison of
multicentre study. Lancet. 2020;395(10231):1208-1216. multiparametric magnetic resonance imaging with prostate-
specific membrane antigen positron-emission tomography
doi: 10.1016/S0140-6736(20)30314-7
imaging in primary prostate cancer diagnosis: A systematic
9. Emmett L, Buteau J, Papa N, et al. The additive diagnostic review and meta-analysis. Cancers (Basel). 2022;14(14):3497.
value of prostate-specific membrane antigen positron doi: 10.3390/cancers14143497
emission tomography computed tomography to
multiparametric magnetic resonance imaging triage in the 18. Wu H, Xu T, Wang X, et al. Diagnostic performance of
diagnosis of prostate cancer (PRIMARY): A prospective 68Gallium labelled prostate-specific membrane antigen
multicentre study. Eur Urol. 2021;80(6):682-689. positron emission tomography/computed tomography and
magnetic resonance imaging for staging the prostate cancer
doi: 10.1016/j.eururo.2021.08.002
with intermediate or high risk before radical prostatectomy:
10. Kawada T, Yanagisawa T, Rajwa P, et al. Diagnostic A systematic review and meta-analysis. World J Mens Health.
performance of prostate-specific membrane antigen 2020;38(2):208-219.

Volume 2 Issue 4 (2024) 7 doi: 10.36922/arnm.4590